These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17671147)

  • 1. HKI-272 in non small cell lung cancer.
    Wong KK
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4593-6. PubMed ID: 17671147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Johnson BE; Jänne PA
    Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
    Li D; Shimamura T; Ji H; Chen L; Haringsma HJ; McNamara K; Liang MC; Perera SA; Zaghlul S; Borgman CL; Kubo S; Takahashi M; Sun Y; Chirieac LR; Padera RF; Lindeman NI; Jänne PA; Thomas RK; Meyerson ML; Eck MJ; Engelman JA; Shapiro GI; Wong KK
    Cancer Cell; 2007 Jul; 12(1):81-93. PubMed ID: 17613438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
    Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
    Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
    Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
    Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
    Shimamura T; Ji H; Minami Y; Thomas RK; Lowell AM; Shah K; Greulich H; Glatt KA; Meyerson M; Shapiro GI; Wong KK
    Cancer Res; 2006 Jul; 66(13):6487-91. PubMed ID: 16818618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
    Ji H; Li D; Chen L; Shimamura T; Kobayashi S; McNamara K; Mahmood U; Mitchell A; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Kim W; Jänne PA; Shapiro GI; Tenen D; Johnson BE; Weissleder R; Sharpless NE; Wong KK
    Cancer Cell; 2006 Jun; 9(6):485-95. PubMed ID: 16730237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
    Riely GJ; Politi KA; Miller VA; Pao W
    Clin Cancer Res; 2006 Dec; 12(24):7232-41. PubMed ID: 17189394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
    Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small cell lung cancer and targeted therapies.
    Blackhall FH; Shepherd FA
    Curr Opin Oncol; 2007 Mar; 19(2):103-8. PubMed ID: 17272981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting.
    Langer CJ
    Clin Lung Cancer; 2008 Sep; 9(5):249-51. PubMed ID: 18824445
    [No Abstract]   [Full Text] [Related]  

  • 20. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
    Bose P; Ozer H
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1735-51. PubMed ID: 19780706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.